Page last updated: 2024-11-08

yh 1885

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

YH 1885: proton pump inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID204103
CHEMBL ID1257753
MeSH IDM0282542

Synonyms (55)

Synonym
yh-1885
sb-641257a
revanex
revaprazan hydrochloride
D05722
178307-42-1
revaprazan hydrochloride (usan)
5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride
4-(3,4-dihydro-1-methyl-2(1h)-isoquinolinyl)-n-(4-fluorophenyl)-5,6-dimethyl-2-pyrimidinamine hydrochloride
2-pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1h)-isoquinolinyl)-n-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride
unii-4dq6t10r64
n-(4-fluorophenyl)-5,6-dimethyl-4-((1rs)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl)pyrimidin-2-amine monohydrochloride
yh 1885
revaprazan hydrochloride [usan]
sb 641257a
4dq6t10r64 ,
revaprazan hcl
yh1885
CHEMBL1257753
FT-0674394
AM84626
n-(4-fluorophenyl)-5,6-dimethyl-4-(1-methyl-3,4-dihydroisoquinolin-2(1h)-yl)pyrimidin-2-amine monohydrochloride, (+/-)-
revaprazan hydrochloride [who-dd]
n-(4-fluorophenyl)-5,6-dimethyl-4-[(1rs)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]pyrimidin-2-amine monohydrochloride
(+/-)-n-(4-fluorophenyl)-5,6-dimethyl-4-(1-methyl-3,4-dihydroisoquinolin-2(1h)-yl)pyrimidin-2-amine monohydrochloride
revaprazan hydrochloride [mi]
2-pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1h)-isoquinolinyl)-n-(4-fluorophenyl)-5,6-dimethyl-, hydrochloride (1:1)
sb-641257 hydrochloride
revaprazan hydrochloride [mart.]
S5058
5,6-dimethyl -2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride
5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)-pyrimidine hydrochloride
5,6-dimethyl -2-(4-fluorophenyamino)-4-(1-methyl -1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine hydrochloride
5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroiso-quinolin-2-yl)pyrimidine hydrochloride
MALPZYQJEDBIAK-UHFFFAOYSA-N
AC-31737
J-524220
AKOS030524777
n-(4-fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydroisoquinolin-2(1h)-yl)pyrimidin-2-amine hydrochloride
HY-N7067
revaprazan (hydrochloride)
178307-42-1 (hcl)
DTXSID30939071
n-(4-fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydroisoquinolin-2(1h)-yl)pyrimidin-2-amine--hydrogen chloride (1/1)
BCP09645
CCG-268641
AT19932
CS-0009632
Q27259461
MS-26753
n-(4-fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)pyrimidin-2-amine;hydrochloride
A881403
BR164337
revaprazan hydrochloride- bio-x
revaprazanhydrochloride

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" After iv administration of YH1885, 5-20 mg kg(-1), to rats, the pharmacokinetic parameters of YH1885 seem to be independent of the drug at the dose ranges studied."( Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats.
Han, KS; Kim, YG; Lee, JW; Lee, MG; Yoo, JK, 1998
)
0.3
"To evaluate the pharmacokinetic and pharmacodynamic characteristics of YH1885, a novel proton pump inhibitor, a single-blind, randomized, placebo-controlled, dose-rising, parallel-group study was conducted in 46 healthy volunteers."( Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.
Bae, KS; Cho, JY; Chung, JY; Jang, IJ; Lim, HS; Moon, BS; Shin, SG; Shon, JH; Song, KS; Yi, SY; Yu, KS, 2004
)
0.32
" Tegoprazan 50 mg or revaprazan 200 mg was administered orally, once daily for 7 days; 24-h intragastric pH monitoring and serum gastrin were measured for pharmacodynamic evaluation."( Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects.
Ban, MS; Jang, IJ; Ji, SC; Kim, B; Lee, S; Nam, JY; Oh, J; Song, GS; Sunwoo, J; Yu, KS, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" The reason for the low extent of bioavailability (F) of YH1885 after oral administration of the drug to rats and the absorption of the drug from various rat gastrointestinal (GI) segments were also investigated."( Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats.
Han, KS; Kim, YG; Lee, JW; Lee, MG; Yoo, JK, 1998
)
0.3
"3 microM), appears to contribute to the dose-dependent bioavailability of the drug."( The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers.
Chung, SJ; Kim, DC; Kim, HS; Lee, JW; Li, H; Shim, CK, 2001
)
0.31
" However, due to poor water solubility, oral bioavailability of the drug was relatively low."( Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.
Chen, Y; Fang, L; Li, W; Mu, L; Tian, Y; Xu, X; Yang, Y; Zhang, Y, 2011
)
0.37
"The objective of this study was to compare the bioavailability and tolerability of revaprazan and itopride combination therapy to those of equally dosed monotherapies to acquire basic drug-drug interaction information about revaprazan."( Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers.
Bae, KS; Choi, HY; Jang, SB; Jin, SJ; Kim, MJ; Kim, YH; Lee, SJ; Lim, HS; Noh, YH; Sung, H, 2012
)
0.38
"In order to investigate the influence of drug physicochemical properties on bioavailability of water insoluble drug nanosuspensions, five drug nanosuspensions were prepared using high pressure homogenization."( Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions.
Cheng, J; Cun, D; Fang, L; Li, W; Liu, J; Quan, P; Xiang, R; Zhang, Y, 2014
)
0.4
"3-fold improved oral bioavailability in comparison with revaprazan powder."( Novel revaprazan-loaded gelatin microsphere with enhanced drug solubility and oral bioavailability.
Choi, HG; Din, FU; Jeong, SC; Jin, SG; Kim, DS; Kim, JO; Kim, JS; Oh, KT; Park, JH; Yong, CS; Youn, YS; Yousaf, AM, 2018
)
0.48
"To enhance the oral bioavailability of revaprazan (RVP), a novel solid, supersaturable micelle (SSuM) was developed."( Development of a Solid Supersaturable Micelle of Revaprazan for Improved Dissolution and Oral Bioavailability Using Box-Behnken Design.
Choi, JY; Choi, YW; Goo, YT; Kim, CH; Kim, HK; Kim, MS; Sa, CK, 2021
)
0.62
"A self-nanoemulsifying drug delivery system (SNEDDS) was developed to enhance the dissolution and oral bioavailability (BA) of revaprazan (RVP)."( Enhanced dissolution and bioavailability of revaprazan using self-nanoemulsifying drug delivery system.
Choi, YW; Goo, YT; Kang, MJ; Kim, CH; Kim, HK; Kim, MS; Lee, S; Sa, CK; Sin, GH, 2022
)
0.72
" Solid lipid nanoparticles (SLNs) have emerged as a drug delivery system capable of enhancing dissolution and bioavailability of lipid soluble drugs."( Sodium alginate-based smart gastro-retentive drug delivery system of revaprazan loaded SLNs; Formulation and characterization.
Al Awadh, AA; Alamri, AH; Alasiri, A; Din, FU; Khan, S; Lahiq, AA; Raja, HN; Shabbir, K, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Previous studies have suggested that the AUC and C(max) of orally dosed YH1885 are dose-dependent in the range of 2 to 500 mg/kg."( The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers.
Chung, SJ; Kim, DC; Kim, HS; Lee, JW; Li, H; Shim, CK, 2001
)
0.31
" The volunteers were randomly allocated to single dose groups of 60 mg, 100 mg, 150 mg, 200 mg, and 300 mg (6 subjects per dose, including 2 placebos) or to multiple-dose groups of 150 mg and 300 mg (once-daily dosing for 7 days; 8 subjects per dose, including 2 placebos)."( Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.
Bae, KS; Cho, JY; Chung, JY; Jang, IJ; Lim, HS; Moon, BS; Shin, SG; Shon, JH; Song, KS; Yi, SY; Yu, KS, 2004
)
0.32
"The objective of this study was to compare the bioavailability and tolerability of revaprazan and itopride combination therapy to those of equally dosed monotherapies to acquire basic drug-drug interaction information about revaprazan."( Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers.
Bae, KS; Choi, HY; Jang, SB; Jin, SJ; Kim, MJ; Kim, YH; Lee, SJ; Lim, HS; Noh, YH; Sung, H, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID517022Inhibition of H+/K+/ATPase2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
Novel pyrimidines as acid pump antagonists (APAs).
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (10.34)18.2507
2000's3 (10.34)29.6817
2010's16 (55.17)24.3611
2020's7 (24.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.64 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index5.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (13.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]